Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Review article: Biomedical intelligence

Vol. 145 No. 5152 (2015)

Antimicrobial stewardship in the intensive care setting – a review and critical appraisal of the literature

  • Dominik Mertz
  • Annie Brooks
  • Neal Irfan
  • Melani Sung
DOI
https://doi.org/10.4414/smw.2015.14220
Cite this as:
Swiss Med Wkly. 2015;145:w14220
Published
13.12.2015

Summary

BACKGROUND: Many antimicrobial stewardship programmes (ASPs) target the intensive care unit owing to high antimicrobial utilisation. In this review, we summarise and assess the quality of evidence supporting the implementation of various ASP strategies in the intensive care unit setting with a focus on publications between 2010 and 2015.

METHODS: We searched Medline up to April 2015 and screened publications of interest for additional relevant articles. We grouped the strategies into four categories: audit and feedback, formulary restrictions, guidelines/clinical pathways, and procalcitonin. We used GRADE terminology to describe the quality of evidence.

RESULTS AND CONCLUSIONS: We identified several studies reporting optimisation and reduction of antibiotic utilisation as well as cost reduction in all four strategies. Randomised controlled trials reviewing the role of procalcitonin demonstrate a moderate level of evidence. Given the lack of randomised controlled trials to support the role of guidelines, formulary restrictions, and audit and feedback, the level of evidence supporting these strategies is low. Importantly, there is no convincing evidence to support the main goal of ASP, namely to improve patient outcomes. Larger, rigorous long-term studies using a cluster randomised controlled trial or at least a controlled quasi-experimental design with time series are required to assess the impact of ASP on patient-important outcomes and on the emergence of resistance in the intensive care unit setting.

References

  1. Dellit TH, Owens RC, McGowan JE, Jr., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.
  2. Srigley JA, Brooks A, Sung M, Yamamura D, Haider S, Mertz D. Inappropriate use of antibiotics and Clostridium difficile infection. Am J Infect Control. 2013;41(11):1116–8.
  3. Polgreen PM, Chen YY, Cavanaugh JE, et al. An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28(2):212–4.
  4. Cusini A, Rampini SK, Bansal V, et al. Different patterns of inappropriate antimicrobial use in surgical and medical units at a tertiary care hospital in Switzerland: a prevalence survey. PLoS One. 2010;5(11):e14011.
  5. Bugnon-Reber A, de Torrente A, Troillet N, Genne D. Antibiotic misuse in medium-sized Swiss hospitals. Swiss Med Wkly. 2004;134(33-34):481–5.
  6. Reimann HA. The misuse of antimicrobics. Med Clin North Am. 1961;45:849–56.
  7. Blaettler L, Mertz D, Frei R, et al. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997–2007. Infection. 2009;37(6):534–9.
  8. Ansari F, Erntell M, Goossens H, Davey P. The European surveillance of antimicrobial consumption (ESAC) point-prevalence survey of antibacterial use in 20 European hospitals in 2006. Clin Infect Dis. 2009;49(10):1496–504.
  9. McGowan JE, Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis. 2001;7(2):286–92.
  10. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36(11):1433–7.
  11. Johnson AP, Woodford N. Global spread of antibiotic resistance: the example of New Delhi metallo-beta-lactamase (NDM)-mediated carbapenem resistance. J Med Microbiol. 2013;62(Pt 4):499–513.
  12. Boucher HW, Talbot GH, Benjamin DK, Jr., et al. 10 x '20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–94.
  13. Aldeyab MA, Harbarth S, Vernaz N, et al. Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. Antimicrob Agents Chemother. 2009;53(5):2082–8.
  14. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96.
  15. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother. 2011;66(6):1223–30.
  16. Fraser GL, Stogsdill P, Dickens JD, Jr., Wennberg DE, Smith RP, Jr., Prato BS. Antibiotic optimization. An evaluation of patient safety and economic outcomes. Arch Intern Med. 1997;157(15):1689–94.
  17. Solomon DH, Van Houten L, Glynn RJ, et al. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med. 2001;161(15):1897–902.
  18. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706.
  19. LaRocco A, Jr. Concurrent antibiotic review programs – a role for infectious diseases specialists at small community hospitals. Clin Infect Dis. 2003;37(5):742–3.
  20. Elligsen M, Walker SA, Pinto R, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol. 2012;33(4):354–61.
  21. Wang HY, Chiu CH, Huang CT, et al. Blood culture-guided de-escalation of empirical antimicrobial regimen for critical patients in an online antimicrobial stewardship programme. Int J Antimicrob Agents. 2014;44(6):520–7.
  22. Bornard L, Dellamonica J, Hyvernat H, et al. Impact of an assisted reassessment of antibiotic therapies on the quality of prescriptions in an intensive care unit. Med Mal Infect. 2011;41(9):480–5.
  23. Amer MR, Akhras NS, Mahmood WA, Al-Jazairi AS. Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia. Ann Saudi Med. 2013;33(6):547–54.
  24. DiazGranados CA. Prospective audit for antimicrobial stewardship in intensive care: impact on resistance and clinical outcomes. Am J Infect Control. 2012;40(6):526–9.
  25. Katsios CM, Burry L, Nelson S, et al. An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patients. Crit Care. 2012;16(6):R216.
  26. Leung V, Gill S, Sauve J, Walker K, Stumpo C, Powis J. Growing a “positive culture” of antimicrobial stewardship in a community hospital. Can J Hosp Pharm. 2011;64(5):314–20.
  27. Rimawi RH, Mazer MA, Siraj DS, Gooch M, Cook PP. Impact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcome. Crit Care Med. 2013;41(9):2099–107.
  28. Ijo I, Feyerharm J. Pharmacy intervention on antimicrobial management of critically ill patients. Pharm Pract (Granada). 2011;9(2):106–9.
  29. Seligman SJ. Reduction in antibiotic costs by restricting use of an oral cephalosporin. Am J Med. 1981;71(6):941–4.
  30. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O’Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med. 1991;90(4):439–44.
  31. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm. 1995;52(13):1433–5.
  32. White AC, Jr., Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis. 1997;25(2):230–9.
  33. Britton HL, Schwinghammer TL, Romano MJ. Cost containment through restriction of cephalosporins. Am J Hosp Pharm. 1981;38(12):1897–900.
  34. Hayman JN, Sbravati EC. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions. Am J Hosp Pharm. 1985;42(6):1343–7.
  35. Woodward RS, Medoff G, Smith MD, Gray JL, 3rd. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med. 1987;83(5):817–23.
  36. Sistanizad M, Kouchek M, Miri M, et al. Carbapenem Restriction and its Effect on Bacterial Resistance in an Intensive Care unit of a Teaching Hospital. Iran J Pharm Res. 2013;12(3):503–9.
  37. Guarascio AJ, Slain D, McKnight R, et al. A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital. Int J Clin Pharm. 2013;35(1):145–8.
  38. Sharma PR, Barman P. Antimicrobial consumption and impact of “Reserve antibiotic indent form” in an intensive care unit. Indian J Pharmacol. 2010;42(5):297–300.
  39. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA. 2000;283(6):749–55.
  40. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162(2 Pt 1):505–11.
  41. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med. 1999;27(10):2118–24.
  42. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29(6):1109–15.
  43. South M, Royle J, Starr M. A simple intervention to improve hospital antibiotic prescribing. Med J Aust. 2003;178(5):207–9.
  44. Chiu CH, Michelow IC, Cronin J, Ringer SA, Ferris TG, Puopolo KM. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J. 2011;30(4):273–8.
  45. Rodriguez L, Jung HS, Goulet JA, Cicalo A, Machado-Aranda DA, Napolitano LM. Evidence-based protocol for prophylactic antibiotics in open fractures: improved antibiotic stewardship with no increase in infection rates. J Trauma Acute Care Surg. Sep 2014;77(3):400–7; discussion 407–8; quiz 524.
  46. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003;37(2):180–6.
  47. Girotti MJ, Fodoruk S, Irvine-Meek J, Rotstein OD. Antibiotic handbook and pre-printed perioperative order forms for surgical antibiotic prophylaxis: do they work? Can J Surg. 1990;33(5):385–8.
  48. Meyer E, Schwab F, Pollitt A, Bettolo W, Schroeren-Boersch B, Trautmann M. Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit. Infection. 2010;38(1):19–24.
  49. Chaves NJ, Ingram RJ, MacIsaac CM, Buising KL. Sticking to minimum standards: implementing antibiotic stewardship in intensive care. Intern Med J. 2014;44(12a):1180–7.
  50. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program for antibiotics and other antiinfective agents. N Engl J Med. 1998;338(4):232–8.
  51. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother. 1999;33(10):1026–31.
  52. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996;124(10):884–90.
  53. Mullett CJ, Evans RS, Christenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support program. Pediatrics. 2001;108(4):E75.
  54. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma’luf N, Bates DW. Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial. J Am Med Inform Assoc. 1998;5(6):554–62.
  55. Nachtigall I, Tafelski S, Deja M, et al. Long-term effect of computer-assisted decision support for antibiotic treatment in critically ill patients: a prospective “before/after” cohort study. BMJ Open. 2014;4(12):e005370.
  56. Ananda-Rajah MR, McBryde ES, Buising KL, et al. The role of general quality improvement measures in decreasing the burden of endemic MRSA in a medical-surgical intensive care unit. Intensive Care Med. 2010;36(11):1890–8.
  57. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Inappropriate antibiotic use due to decreased compliance with a ventilator-associated pneumonia computerized clinical pathway: implications for continuing education and prospective feedback. Pharmacotherapy. 2012;32(8):755–63.
  58. Slain D, Sarwari AR, Petros KO, et al. Impact of a Multimodal Antimicrobial Stewardship Program on Pseudomonas aeruginosa Susceptibility and Antimicrobial Use in the Intensive Care Unit Setting. Crit Care Res Pract. 2011;2011:416426.
  59. Dortch MJ, Fleming SB, Kauffmann RM, Dossett LA, Talbot TR, May AK. Infection reduction strategies including antibiotic stewardship protocols in surgical and trauma intensive care units are associated with reduced resistant gram-negative healthcare-associated infections. Surg Infect (Larchmt). 2011;12(1):15–25.
  60. Hausfater P, Garric S, Ayed SB, Rosenheim M, Bernard M, Riou B. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin. Infect. Dis. 2002;34(7):895–901.
  61. Prkno A, Wacker C, Brunkhorst FM, Schlattmann P. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock – a systematic review and meta-analysis. Crit. Care. 2013;17(6):R291.
  62. Annane D, Maxime V, Faller JP, et al. Procalcitonin levels to guide antibiotic therapy in adults with non-microbiologically proven apparent severe sepsis: a randomised controlled trial. BMJ Open. 2013;3(2).
  63. Bouadma L, Luyt CE, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463–74.
  64. Hochreiter M, Kohler T, Schweiger AM, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009;13(3):R83.
  65. Jensen JU, Hein L, Lundgren B, et al. Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med. 2011;39(9):2048–58.
  66. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372(21):1996–2005.
  67. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–64.
  68. Clec’h C, Fosse JP, Karoubi P, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med. 2006;34(1):102–7.
  69. Shehabi Y, Sterba M, Garrett PM, et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med. 2014;190(10):1102–10.
  70. Hohn A, Heising B, Hertel S, Baumgarten G, Hochreiter M, Schroeder S. Antibiotic consumption after implementation of a procalcitonin-guided antimicrobial stewardship programme in surgical patients admitted to an intensive care unit: a retrospective before-and-after analysis. Infection. 2015.
  71. Albrich WC, Harbarth S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Intensive Care Med. 2015.
  72. Angebault C, Andremont A. Antimicrobial agent exposure and the emergence and spread of resistant microorganisms: issues associated with study design. Eur J Clin Microbiol Infect Dis. 2013;32(5):581–95.
  73. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.
  74. Burke JP. Antibiotic resistance – squeezing the balloon? JAMA. 1998;280(14):1270–1.
  75. Harrison M, Collins CD. Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? Infect Control Hosp. Epidemiol. 2015;36(3):265–72.